spacer
home > ebr > summer 2017 > what about pichia?
PUBLICATIONS
European Biopharmaceutical Review

What about Pichia?

From the list of therapeutic protein approvals, two pre-eminent hosts appear to dominate the field of recombinant protein expression: the bacterial Escherichia coli (E. coli) system and mammalian cell lines, such as Chinese hamster ovary (CHO) cells. Combining the advantages of these, the versatile yeast Pichia pastoris* (P. pastoris) is emerging to become a competitive alternative for biomanufacturing.

Major Player Potential


P. pastoris is an established, FDA and EMA approved, generally recognised as safe and highly competitive expression host. It has strong and effective secretory capacities, which often result in double-digit g/l levels of recombinant protein in the culture supernatant, while retaining most endogenous proteins within the cells. Delivering a secreted raw product with a high purity in the culture supernatant, P. pastoris enables simplified downstream procedures, which, when paired with cultivation processes with a high volumetric productivity, result in highly economic protein production.

This yeast combines the advantages of prokaryotes and mammalian cells: it is amenable to genetic manipulation. Pichia exhibits fast growth on cheap and chemically-defined media comparable to bacteria, together with eukaryotic features like a subcellular protein processing system that is required for post-translational modifications. Therefore, the host offers the speed and ease of highly efficient prokaryotic platforms and the secretion capabilities of mammalian expression systems, reducing the struggle for protein purification. Unlike bacterial hosts such as E. coli, no cell lysis and time-consuming isolation from a crude lysate is required to obtain the target protein in pure form. Reaction steps, like refolding from inclusion bodies, are obsolete and unwanted enzymatic side activities are minimised.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Thomas Purkarthofer, PhD, is Head of Business Development at VTU Technology GmbH, after joining the company in 2006 to manage the start-up of VTU’s new Protein Technologies Unit. Thomas received his PhD in chemistry from Graz University of Technology, Austria, and was engaged in and managed several international industrial biotechnology R&D projects and is co-author of several peer-reviewed publications.

Iskandar Dib studied at Graz University of Technology, Austria, and the Research Center Applied Biocatalysis, Austria. After obtaining his PhD, he joined the team of VTU Technology where he is now Principal R&D Manager, Process Development and Analytics department. His areas of expertise include process development for up- and downstream processes applying DoE tools for process understanding.

Evelyn Trummer-Gödl, PhD, holds a master’s degree and a doctorate in biotechnology from the University of Natural Resources and Life Sciences, Austria. She has used her previous experience in industrial protein expression and cell culture to contribute to VTU’s marketing and business development team.
spacer
Thomas Purkarthofer
spacer
spacer
spacer
Iskandar Dib
spacer
spacer
spacer
Evelyn Trummer-Gödl
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

World-leading cancer stem cell expert joins Avacta Scientific Advisory Board

Developer of biotherapeutics and research reagents announces the appointment of Professor Gerard Evan to its Scientific Advisory Board
More info >>

White Papers

SuperCapSyringe®

Weibel CDS AG

Safer, easier and faster drug delivery – Weibel CDS AG, Switzerland develops and produces innovative, user friendly, application oriented injections systems and devices. The SuperCapSyringe® product family upgrades your vial practically to a prefilled syringe. Based on a modular design, the syringe is fully adaptable to your application needs. It is supplied in different sizes and, as a novelty, with staked needles including a passive safety device.
More info >>

 
Industry Events

7th annual Orphan Drugs and Rare Diseases UK

18-19 October 2017, Holiday Inn Kensington Forum, London

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement